The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
(meta data) TITLE: * :: Scrip We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Scrip is part of Informa PLC Informa PLC About us Investor relations This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. Other Products: Generics Bulletin | Medtech Insight | In Vivo Pink Sheet | HBW Insight | Report Store Start Trial Sign In This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183 Printed By Existing Subscriber? Sign in to continue reading. Sign In New to Scrip? Start a free trial today! Free Trial Register for our free email digests: Existing Subscriber? Sign in to continue reading. Sign In New to Scrip? Start a free trial today! Free Trial Register for our free email digests: Brought to you by # Neurocrine Biosciences raises $34.2mm in IPO of 3.5mm shares. May 1996 ### Executive Summary Neurocrine Biosciences (therapeutics for disorders of the central nervous and immune systems) has completed an initial public offering of 3.5mm shares priced at $10.50 per share, raising a net of $34.18mm. ###### Deal Industry Drug Discovery Tools Drug Discovery Tools Molecular Diversity ###### Deal Status ###### Deal Type Already a Strategic Transactions subscriber? You have access to the full deal record through your subscription Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products. Questions? Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com ## Related Companies Neurocrine Biosciences Inc. Not all deals are the same. Rely on the pioneer in deal making intelligence – Strategic Transactions for analyzing and tracking healthcare deals. With over 20 years of global M&A, financing, and alliance activity – Strategic Transactions is the premium source that top pharmaceutical firms, PLUS leaders in medical devices, diagnostics, finance, and consulting turn to for the best available intelligence for deals in the industry. ### You must sign in to use this functionality Sign In ### Authentication.SignIn.HeadSignInHeader Sign In ### Register Your username does not meet the requirements. Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support. Neurocrine Biosciences raises $34.2mm in IPO of 3.5mm shares. ### Email Deal All set! This article has been sent to my@email.address. All fields are required. For multiple recipients, separate email addresses with a semicolon. Please make sure all fields are completed. Please enter a valid e-mail address Please make sure you have filled out all fields Please make sure you have filled out all fields Subject: Neurocrine Biosciences raises $34.2mm in IPO of 3.5mm shares. Add a personalized message to your email DCD.EmailPopout.Notice
train22013
Neurocrine Biosciences
History.
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed by Avalon Ventures among others. 
 In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome.